Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
Titel:
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
Auteur:
Loomba, Rohit Kowdley, Kris V Rodriguez, Jose Kim, Nomita J Alvarez, Alina Maria Morrow, Linda Jeglinski, Brenda Clawson, Alicia Chowdhury, Swapan Bain, Gerard Odrljin, Tatjana